ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2010

May 18, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2010-05-13

Reporting Person: WINSTEAD DWIGHT (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-05-13	Common Stock	M	1405	$2.69	Acquired	1405	Direct
2010-05-13	Common Stock	S	1405	$19.1999	Disposed	0	Direct
2010-05-17	Common Stock	M	15595	$2.69	Acquired	15595	Direct
2010-05-17	Common Stock	M	8260	$7.25	Acquired	23855	Direct
2010-05-17	Common Stock	S	23855	$18.5348	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-05-13	stock option (right to buy)	$2.69	M	1405	Disposed	2015-10-28	Common Stock (1405)	Direct
2010-05-17	Stock option (right to buy)	$2.69	M	15595	Disposed	2015-10-28	Common stock (15595)	Direct
2010-05-17	Stock option (right to buy)	$7.25	M	8260	Disposed	2010-07-08	Common Stock (8260)	Direct

Footnotes

F1: This is the weighted average price. The prices ranged from $18.40 to $18.86. The reporting person undertakes to provide on request a detailed breakout of the pricing.